Company Overview and News

4
The Singapore stocks to watch amid Trump and Kim's historic meet

2018-06-11 theedgemarkets
SINGAPORE (June 11): There’s more than one way to play the Trump-Kim summit in the world of stocks.
S07 G13 0069 SHALF GIGNF O39 GIGNY SHALY

4
The Singapore Stocks to Watch While Trump Meets Kim - Bloomberg

2018-06-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
S07 G13 0069 SHALF GIGNF O39 GIGNY SHALY

10
The Singapore stocks to watch during the Trump-Kim summit

2018-06-10 scmp
There’s more than one way to play the Trump-Kim summit in the world of stocks. Apart from the obvious North Asian and US equities, there’s another geography investors can consider: Singapore – and its consumer stocks, to be precise.
S07 C6L SK7 CDGLF BTKGF 5DA ACTRF SHALF SINGY Q5T O39 GIGNY 42R A68U G13 0069 CDGLY H15 A34 GIGNF FHOSY J85 SHALY SINGF

64
Healthcare Recovery Side Effect: U.S. Moats Rebound

2018-06-01 seekingalpha
U.S. moat companies rebounded in April, with the U.S.-oriented Morningstar® Wide Moat Focus IndexSM (MWMFTR, or "U.S. Moat Index") leading the broad U.S. market as represented by the S&P 500® Index (1.47% vs. 0.38%, respectively). International moats failed to outperform the broad international markets for the first month since January 2018. Represented by the Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN, or "International Moat Index"), international moats trailed the MSCI All Country World Index ex-USA in April (1.
G13 HSYFB PEP KIGRY MCK GIGNF CVS MORN AET GIGNY HSY

1
Genting's former finance vice president gets S$50,000 penalty for insider trading

2018-05-11 channelnewsasia
SINGAPORE: A former senior executive of Genting Singapore has been slapped with a civil penalty of S$50,000 for committing insider trading.
G13 GIGNF GIGNY

1
Chinese Tycoon Flips 007 Casino for All-in Bet on Korean Island - Bloomberg

2018-04-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
G13 LIDVF GIGNF GIGNY

2
Chinese tycoon flips 007 casino for all-in bet on South Korean island

2018-04-16 bworldonline
Soon after property tycoon Yang Zhihui bet his fortune on luring Chinese gamblers and investors to a giant casino resort project in South Korea, his ambitions were threatened by an economic war that flared up between the two nations. Yang not only weathered the political spat over North Korea’s nuclear program, but his massive project expanded and his company announced this month it would build another casino in the Philippines.
G13 LIDVF GIGNF GIGNY

7
Genting plans to bid for Japan gaming licence

2018-04-09 thestar.com.my
PETALING JAYA: Genting Bhd is optimistic that the Japan Integrated Resort Execution Bill will be tabled in this year’s Diet session, paving the way for the group to formally bid for its Japan gaming licence.
GMALY G13 4715 GMALF 2291 GIGNF GEBHF GIGNY

4
Japan Casino Law Picks Up Steam: Las Vegas Sands, Leading Candidate, Could Get Knock On Effect Very Soon

2018-03-29 seekingalpha
LVS will invest up to $10bn on a property we think could generate over $5billion in GGR if they win Osaka.
G13 WYNN LVS GIGNF GIGNY

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...